TO THE EDITOR: Neurotoxicity from anti-CD19 chimeric antigen receptor (CAR) T cells, an effective immunotherapy for refractory B-cell malignancies,[1][1][⇓][2][⇓][3][⇓][4][⇓][5]-[6][6] is common and poorly understood. Commonly manifesting as headache, delirium, language disturbances and
No takes yet. Share an insight, caveat, or question.
Nellan et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: